Novartis sees new model in BioE deal
This article was originally published in Scrip
Novartis has signed a deal for typhoid vaccines with Indian firm Biological-E which it hopes will form the basis for a new, more effective model to get products for neglected diseases to people in poor countries. According to Don Ganem, vice-president and global head of infectious diseases at the Novartis Institutes for BioMedical Research, it represents "a prototype for how we would like to operate in the area of neglected diseases: not just vaccines, but also drugs."
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.